title: Serum tumor necrosis factor for monitoring response of hepatic veno-occlusive disease to pentoxiphyllin--a case report.
abstract: Hepatic veno-occlusive disease (VOD) is the second most common cause of death after autologous bone marrow transplantation (ABMT). A patient with multiple myeloma undergoing ABMT developed classic features of hepatic VOD. He responded to treatment with pentoxiphyllin. Serum tumor necrosis factor (TNF) levels showed remarkable correlation with the severity of VOD and response to therapy.
authors.affiliation: Department of Medical Oncology, Tata Memorial Hospital Parel, Mumbai, India.
authors.forename: P M
authors.initials: PM
authors.lastname: Parikh
authors.forename: S H
authors.initials: SH
authors.lastname: Advani
authors.forename: J S
authors.initials: JS
authors.lastname: Nadkarni
authors.forename: S
authors.initials: S
authors.lastname: Kulkarni
authors.forename: G
authors.initials: G
authors.lastname: Kapoor
authors.forename: P S
authors.initials: PS
authors.lastname: Sastry
authors.forename: M
authors.initials: M
authors.lastname: Anand
authors.forename: T K
authors.initials: TK
authors.lastname: Saikia
authors.forename: R
authors.initials: R
authors.lastname: Gopal
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D004298:Dopamine / Q000627:therapeutic use; D006504:Hepatic Veno-Occlusive Disease / Q000097:blood* / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000601:surgery; D010431:Pentoxifylline / Q000627:therapeutic use*; D013148:Spironolactone / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D014409:Tumor Necrosis Factor-alpha; D014665:Vasodilator Agents; D013148:Spironolactone; D010431:Pentoxifylline; D004298:Dopamine